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Spinal bulbar muscular atrophy (SBMA) and amyotrophic lateral sclerosis are two distinct forms of motor
neuron disease with different genetic causes, pathology, and clinical course. However, both disorders are
characterized by the progressive loss of lower motor neurons and by a similar protective response to
growth factors in animal models, therefore raising the possibility of an overlap in the ﬁnal pathogenic
cascade. Mutations in the FUS gene and fused in sarcoma (FUS) protein pathology have now been
identiﬁed in some amyotrophic lateral sclerosis cases, while a CAG expansion in the androgen receptor
gene is known to cause SBMA. Recently, multiple lines of evidence have identiﬁed FUS as a major target
of the androgen receptor, suggesting that FUS could be dysregulated in SBMA motor neurons. We have
investigated this possibility by using a well-established mouse model of SBMA and our analysis of
primary motor neuron cultures, spinal cords, and microdissected motor neurons show no evidence for
FUS dysregulation.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Mutations in Fused in Sarcoma (FUS) have been found to cause
up to 4% of familial amyotrophic lateral sclerosis (Ferraiuolo et al.,
2011). Spinal bulbar muscular atrophy (SBMA) is a slowly
progressive adult-onset motor neuron (MN) disease characterized
by the loss of lowerMNs (LMNs) in the spinal cord and brain stem. It
is caused by a CAG repeat expansion in the ﬁrst exon of the
androgen receptor (AR) gene which results in an extended poly-
glutamine tract (AR SBMA poly-Q) (Rhodes et al., 2009). The AR is
a ligand-dependant transcription factor and the AR SBMA poly-Q
expansion has been shown to cause disease through a variety of
mechanisms, including an ampliﬁcation of native AR interactions
and function (Nedelsky et al., 2010).
Amyotrophic lateral sclerosis and SBMA fall under the general
class of MN diseases, but have different genetic causes, pathology,
and clinical course. Nonetheless, both diseases are associated by theodegenerative Disease, UCL
1N 3BG, UK. Tel.: þ44(0)
ll rights reserved.progressive adult onset loss of LMNs, similarities in speciﬁc
pathology ﬁndings, and a positive response of animal models to
general protective treatments (Forsberg et al., 2012; Papanikolaou
and Ellerby, 2009; Sopher et al., 2004). These ﬁndings suggest the
possibility that the diseases share features in the pathogenetic
cascade that leads to neuronal death (Papanikolaou and Ellerby,
2009).
Two recent independent studies, focusing on prostate cancer
cells, have shown that fused in sarcoma (FUS) levels are regulated
by the AR in an androgen-dependent fashion (Brooke et al., 2011;
Haile et al., 2011). These results raise the possibility that FUS might
be misregulated in SBMA, and this might contribute to the MN
degeneration in the disease, offering an intriguing link between
these 2 distinct forms of MN degeneration. Here we investigate this
possible link by determining if FUS expression is dysregulated in
a well characterized SBMA mouse model (AR100) carrying a 100
poly-Q expanded mutation in the AR (Sopher et al., 2004).
2. Methods
Details of mice, embryonic MN culture, laser capture microdis-
section, real-time quantitative polymerase chain reaction, Western
Fig. 1. FUS is normally expressed in the presence of AR100 repeat expansion. FUS messenger RNA (mRNA) levels in embryonic motor neurons, normalized to Actb (A) and Hprt1 (B).
No signiﬁcant (ns) change is present between AR100 and wild type (WT). A signiﬁcant increase in FUS levels is present after dihydrotestosterone (DHT) treatment using 2-way
analysis of variance [F(1,8) ¼ 10.108; p ¼ 0.013]. (C) Protein levels in 3-month-old AR100 (n ¼ 6) and littermate control (WT) (n ¼ 5) spinal cords normalized to b-actin (ns, by
2-tailed unpaired t test; p ¼ 0.62). (D) Protein levels in 12-month-old AR100 (n ¼ 3) and WT (n ¼ 3) spinal cords normalized to b-actin (ns, by 2-tailed unpaired t test; p ¼ 0.49). FUS
mRNA expression in laser capture microdissection motor neurons (MNs) of AR100 and WT mice, normalized to Actb (E) and Gapdh (F) (ns, by 2-tailed unpaired t test; p ¼ 0.30, p ¼
0.63, respectively). Fused in sarcoma protein (Fus) localization is normal in 18-month-old AR100 mice MNs. Confocal images from lumbar spinal cord sections of WT (GeJ) and
AR100 (KeN) mice. Choline acetyltransferase (ChAT) (green), Fus (red), DAPI (blue). Fus appears to localize mainly in the nucleus of MNs and other cell types in both genotypes.
P. Fratta et al. / Neurobiology of Aging 34 (2013) 1516.e17e1516.e191516.e18blot, and immunohistochemistry methods are given in the
Supplementary data.
3. Results
To assess the effect of the AR SBMA poly-Q repeat expansion
and dihydrotestosterone (DHT) on FUS regulation in MNs, we
initially determined FUS messenger RNA (mRNA) levels in
puriﬁed embryonic MN (eMN) cultures obtained from AR100
and wild type (WT) littermate embryos. Taqman analysis
showed that DHT treatment increases FUS levels [F(1,8) ¼
10.108; p ¼ 0.013], but there was no signiﬁcant differencebetween AR100 and WT eMNs in both DHT-treated and
untreated conditions. (Fig. 1A and B).
To assess if the presence of the AR SBMA poly-Q repeat
expansion caused a change in FUS levels in the context of the
mature adult central nervous system, we tested FUS protein
levels in spinal cord lysates of presymptomatic 3-month-old
mice. The results showed no signiﬁcant difference in FUS
protein levels between AR100 mice and littermate WT controls
(Fig. 1C).
FUS protein levels in the spinal cord come from an extremely
diverse population of cells and this might mask possible differences
present in speciﬁc cell types. We therefore analyzed FUS mRNA
P. Fratta et al. / Neurobiology of Aging 34 (2013) 1516.e17e1516.e19 1516.e19levels speciﬁcally in LMNs isolated by laser capturemicrodissection.
However, no signiﬁcant changes were observed in AR100 LMNs
(Fig. 1E and F).
Finally, to test if FUS dysregulation plays a role during the active
disease process, we analyzed FUS protein levels in spinal cords of
aged AR100 and control mice and found no signiﬁcant differences
(Fig. 1D). We also investigated FUS localization in lumbar spinal
cord sections from end-stage AR100 and control mice. The staining
revealed that FUS was localized in the nucleus throughout cells in
the spinal cord and also speciﬁcally in MNs, in both genotypes
(Fig. 1GeN).
4. Discussion
FUS,whichwhenmutated can be causative of amyotrophic lateral
sclerosis and is found to mislocalize in patients’ spinal cords
(Ferraiuolo et al., 2011), is known to interact with nuclear hormone
receptors and the AR (Haile et al., 2011; Powers et al., 1998). FUS is
regulated at both the protein and mRNA levels through the AR in
response to androgen stimuli (Brooke et al., 2011; Haile et al., 2011).
These ﬁndings, along with the recent evidence that the mutant
expanded poly-Q AR exerts part of its pathogenicity through misap-
propriation of native function (Nedelsky et al., 2010), have raised the
question as to whether FUS could be misregulated in SBMA.
Our results show that FUSmRNA levels are increased in response
to DHT in both AR100 and control puriﬁed eMNs, but no difference
between AR100 and controls was found. We then analyzed if any
pathologic changes occurred in vivo and, to study the direct effect of
the poly-Q expanded AR, and not secondary disease changes, we
chose to conduct our initial analysis at the presymptomatic age of 3
months. Both FUS protein levels in spinal cord lysates and FUS
mRNA levels in microdissected MNs showed no changes between
AR100 and controls. Finally, we investigated the involvement of FUS
in the active phases of disease by testingmice at advanced and end-
stage time points. However, even at these symptomatic stages of
disease, protein levels were unchanged and FUS localization was
also normal.
In conclusion, our results show that FUS expression is not
altered in the spinal cord or in MNs in AR100 mice and is therefore
not inﬂuenced by the presence of the poly-Q expanded AR or by
secondary changes occurring in active SBMA.Disclosure statement
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Appendix A. Supplementary data
Supplementary data associated with this article and an
extended version of the Introduction, Results, Methods, Discussion
and References can be found, in the online version, at http://dx.doi.
org/10.1016/j.neurobiolaging.2012.09.008.
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